Oct 26 2015
Idarucizumab for Dabigatran Reversal Approved
On Friday, October 16, the FDA approved idarucizumab (Praxbind) as an effective reversal agent for the oral direct thrombin inhibitor, dabigatran (Pradaxa). Click here tor the press release. Thanks to Dr. Paul Riley, Stago-US, for this heads-up.
read more